Drug Combination Targets Triple-Negative Breast Cancer
Researchers find that pairing BRD1 inhibitors with carmofur enhances the death of aggressive cancer cells.
Updated on Oct. 24, 2026 in Cancer
Scientists have identified that combining BRD1 inhibitors with the drug carmofur effectively suppresses tumor growth in triple-negative breast cancer. This dual-action approach triggers increased cell death compared to using either treatment individually.
Why it matters
Triple-negative breast cancer remains one of the most difficult subtypes to treat due to its high mortality rates compared to other forms of the disease. Finding new ways to sensitize these cells to existing drugs could lead to more effective therapeutic strategies for patients.
Researchers observed that the combined application of BAY-299 and carmofur reduced the expression of the anti-apoptotic gene BCL2 while increasing levels of the transcriptional repressor BCL6. This study utilized specific BRD1 inhibitors including BAY-299, NI57, and OF1 to assess antitumor impact.
The details
The treatment works by targeting the protein ASAH1, which is commonly overexpressed in triple-negative breast cancer cells. By utilizing BRD1 inhibitors alongside carmofur, the study successfully induced apoptosis, or programmed cell death, in laboratory models.
Timeline
October 24, 2026: The study outlining these findings was published.
The Big Picture
This discovery extends the reach of the ongoing development of epigenetic inhibitors for oncology by identifying how specific chromatin modifiers can improve the efficacy of existing metabolic inhibitors. The findings mark a potential shift in how researchers combine gene-regulating drugs with standard anticancer agents.
This development represents a preliminary laboratory finding that does not yet impact current clinical treatment or the availability of medication for patients. Further investigation and clinical trials are required before these drug combinations could become a part of standard medical care.
The takeaway
Combining existing pharmacological agents to target specific cancer vulnerabilities is a major focus of modern drug discovery. This study illustrates the potential of using epigenetic inhibitors to enhance the therapeutic success of traditional cancer drugs.
Further reading
For more on the latest research in this field, visit our Cancer section.
Source note: This article includes information reported by Nature.
